Boston Scientific Corp Files 8-K

Ticker: BSX · Form: 8-K · Filed: 2025-05-28T00:00:00.000Z

Sentiment: neutral

Topics: corporate-structure, debt-filing, sec-filing

Related Tickers: BSX

TL;DR

BSX filed an 8-K on 5/28/25, mostly corporate structure and debt notes due 2027.

AI Summary

On May 28, 2025, Boston Scientific Corporation (BSX) filed an 8-K report. The filing primarily contains information related to their corporate structure and financial instruments, including common stock and senior notes due in 2027. No specific new business events or material financial changes were detailed in this particular filing.

Why It Matters

This filing provides an update on Boston Scientific's corporate and financial structure, which is important for investors to track the company's ongoing financial health and obligations.

Risk Assessment

Risk Level: low — The filing is routine and does not disclose any new material adverse events or significant financial changes.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Boston Scientific Corporation?

The primary purpose of this 8-K filing is to report information related to the company's corporate structure and financial instruments, including common stock and senior notes due in 2027.

When was this 8-K report filed by Boston Scientific Corporation?

This 8-K report was filed on May 28, 2025.

What specific financial instruments are mentioned in the filing?

The filing mentions common stock and senior notes due in 2027.

What is Boston Scientific Corporation's principal executive office address?

Boston Scientific Corporation's principal executive office is located at 300 Boston Scientific Way, Marlborough, Massachusetts 01752-1234.

Does this filing indicate any new business operations or material events for Boston Scientific?

Based on the provided text, this filing appears to be routine and primarily concerns corporate and financial structure information, rather than detailing new business operations or material events.

From the Filing

0000885725-25-000033.txt : 20250528 0000885725-25-000033.hdr.sgml : 20250528 20250528074547 ACCESSION NUMBER: 0000885725-25-000033 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250528 ITEM INFORMATION: Other Events FILED AS OF DATE: 20250528 DATE AS OF CHANGE: 20250528 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP CENTRAL INDEX KEY: 0000885725 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 042695240 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11083 FILM NUMBER: 25991167 BUSINESS ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 BUSINESS PHONE: 508-683-4000 MAIL ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 8-K 1 bsx-20250528.htm 8-K bsx-20250528 0000885725 false 0000885725 2025-05-28 2025-05-28 0000885725 us-gaap:CommonStockMember 2025-05-28 2025-05-28 0000885725 bsx:SeniorNotedue2027Member 2025-05-28 2025-05-28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________ FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 _____________________________________________________________________ Date of Report (Date of earliest event reported): May 28, 2025 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)      300 Boston Scientific Way , Marlborough , Massachusetts                  01752-1234     (Address of principal executive offices)                           (Zip Code) ( 508 ) 683-4000 (Registrant's telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.01 par value per share BSX New York Stock Exchange 0.625% Senior Notes due 2027 BSX27 New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company    ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐ Item 8.01 Other Events. On May 28, 2025, Boston Scientific Corporation (the “Company”) announced it is discontinuing worldwide sales of the ACURATE neo2™ and ACURATE Prime™ Aortic Valve Systems and no longer pursuing U.S. FDA approval for ACURATE or approval in other geographies. The Company made this decision based on recent discussion

View on Read The Filing